OOIR: Observatory of International Research

Papers

(The H4-Index of Blood is 96. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome	1064
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	1001
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	999
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection	974
Platelet gene expression and function in patients with COVID-19	729
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	593
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19	586
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	526
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	471
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial	454
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	336
Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis	318
Venous thromboembolism in cancer patients: a population-based cohort study	318
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study	300
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition	283
Outcomes of COVID-19 in patients with CLL: a multicenter international experience	244
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	242
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	209
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS	201
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	196
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	195
Postdischarge thrombosis and hemorrhage in patients with COVID-19	185
Glucose-6-phosphate dehydrogenase deficiency	180
The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice	167
NPM1-mutated acute myeloid leukemia: from bench to bedside	167

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies	166
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	164
Therapeutic options in VEXAS syndrome: insights from a retrospective series	162
Antibody-induced procoagulant platelets in severe COVID-19 infection	159
Postdischarge venous thromboembolism following hospital admission with COVID-19	158
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	157
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	153
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study	152
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	150
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	144
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	143
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	143
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	141
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	140
Management of AL amyloidosis in 2020	139
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	136
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	135
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes	130
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	129
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	129
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	126
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	125
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	124
Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study	122
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	122
Developmental trajectory of prehematopoietic stem cell formation from endothelium	121
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	121
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	120
Diamond-Blackfan anemia	120
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	119
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	119
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	118
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	117
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms	117
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	115
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	115
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion	115
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	115
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	113
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	113
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	112
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	110
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	109
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	109
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	109
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	107
Redefining outcomes in immune TTP: an international working group consensus report	107
Use of convalescent plasma in hospitalized patients with COVID-19: case series	107
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis	106
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	106

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	105
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	102
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	102
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	101
Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults	100
The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD	100
Real-world experience with caplacizumab in the management of acute TTP	100
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	99
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	99
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	99
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	99
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	99
How I treat relapsed acute lymphoblastic leukemia in the pediatric population	98
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	98
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	98
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	98
Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor	98
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR	98
BCL2 and MCL1 inhibitors for hematologic malignancies	97
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	97
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	97
HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis	96